Dannielle Appelhans
Director/Miembro de la Junta en GENERATION BIO CO. .
Fortuna: 60 200 $ al 30/04/2024
Cargos activos de Dannielle Appelhans
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
GENERATION BIO CO. | Director/Miembro de la Junta | 15/07/2022 | - |
Cour Pharmaceuticals Development Co., Inc.
Cour Pharmaceuticals Development Co., Inc. BiotechnologyHealth Technology Cour Pharmaceuticals Development Co., Inc. engages in the development of therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease. Its product pipeline include celiac disease, peanut allergy, multiple sclerosis, and neutralizing antibodies. The company was founded by John J. Puisis and Jim Herrmann and is headquartered in Chicago, IL. | Director de Operaciones | 19/07/2023 | - |
Historial de carrera de Dannielle Appelhans
Antiguos cargos conocidos de Dannielle Appelhans.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
RUBIUS THERAPEUTICS | Director Ejecutivo | 15/11/2022 | 03/03/2023 |
Director de Operaciones | 09/08/2021 | 15/11/2022 | |
Presidente | 15/11/2022 | 03/03/2023 | |
AVEXIS INC | Director Técnico/Científico/I+D | 01/01/2020 | 01/01/2021 |
Formación de Dannielle Appelhans.
MIT Sloan School of Management | Masters Business Admin |
University of Michigan | Undergraduate Degree |
Massachusetts Institute of Technology | Graduate Degree |
Estadísticas
Internacional
Estados Unidos | 8 |
Operativa
Chief Operating Officer | 2 |
Chief Executive Officer | 1 |
President | 1 |
Sectorial
Health Technology | 5 |
Consumer Services | 3 |
Finance | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
GENERATION BIO CO. | Health Technology |
Empresas privadas | 3 |
---|---|
Rubius Therapeutics, Inc.
Rubius Therapeutics, Inc. BiotechnologyHealth Technology Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines. It provides medicine for cancer, autoimmune diseases, hemophilia, infectious and metabolic diseases. The company was founded on April 26, 2013 and is headquartered in Foxboro, MA. | Health Technology |
Novartis Gene Therapies, Inc.
Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
Cour Pharmaceuticals Development Co., Inc.
Cour Pharmaceuticals Development Co., Inc. BiotechnologyHealth Technology Cour Pharmaceuticals Development Co., Inc. engages in the development of therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease. Its product pipeline include celiac disease, peanut allergy, multiple sclerosis, and neutralizing antibodies. The company was founded by John J. Puisis and Jim Herrmann and is headquartered in Chicago, IL. | Health Technology |
- Bolsa de valores
- Insiders
- Dannielle Appelhans
- Experiencia